Abdullah F Alharthi
Overview
Explore the profile of Abdullah F Alharthi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
19
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alissa A, Korayem G, Aljuhani O, AlFaifi M, Alnajjar L, Souaan N, et al.
Ther Clin Risk Manag
. 2025 Feb;
21:177-189.
PMID: 40008079
Background: Limited evidence is available regarding the safety and effectiveness of early high protein intake in critically ill patients with COVID-19. Therefore, this study aims to assess the safety of...
2.
Basilim A, Eljaaly K, Aljuhani O, Korayem G, Altebainawi A, Aldhmadi W, et al.
J Intensive Care Med
. 2024 Nov;
40(1):74-84.
PMID: 39552466
Dexmedetomidine (DEX) is a highly favored sedative agent in critically ill patients owing to its anxiolytic and analgesic properties, lower risk of delirium, and minimal respiratory depression. Additionally, DEX exhibits...
3.
Al Sulaiman K, Aljuhani O, Korayem G, AlFaifi M, Alharthi A, Alshehri A, et al.
Infect Drug Resist
. 2024 Jul;
17:3161-3171.
PMID: 39050827
Background: There is increasing evidence suggesting that ABO blood type may play a role in the immunopathogenesis of COVID-19 infection. In addition to ABO blood type, the Rhesus (Rh) factor...
4.
Al Sulaiman K, Aljuhani O, Alkofide H, Aljohani M, Badreldin H, Al Harbi M, et al.
Thromb J
. 2024 May;
22(1):43.
PMID: 38778323
Background: Recent guidelines recommend using direct oral anticoagulants (DOACs) as first-line agents in patients with non-valvular atrial fibrillation (NVAF). Research is currently investigating the use of Apixaban in underweight patients,...
5.
Al Sulaiman K, Aljuhani O, Korayem G, Altebainawi A, Alharbi R, Assadoon M, et al.
BMC Pulm Med
. 2023 Oct;
23(1):392.
PMID: 37848847
No abstract available.
6.
Al Sulaiman K, Aljuhani O, Korayem G, Altebainawi A, Alharbi R, Assadoon M, et al.
BMC Pulm Med
. 2023 Aug;
23(1):315.
PMID: 37641042
Background: Previous studies have shown mortality benefits with corticosteroids in Coronavirus disease-19 (COVID-19). However, there is inconsistency regarding the use of methylprednisolone over dexamethasone in COVID-19, and this has not...
7.
Aljuhani O, Al Sulaiman K, Al Bekairy A, Almajed K, Al Harbi M, Thabit A, et al.
J Infect Public Health
. 2023 Jun;
17 Suppl 1:68-75.
PMID: 37271687
Background: Hajj is the largest mass gathering worldwide that takes place every year in Makkah, Saudi Arabia. This paper aims to provide a comprehensive guide and expectations for delivering and...
8.
Aljuhani O, Korayem G, Altebainawi A, Alotaibi M, Alrakban N, Ghoneim R, et al.
Saudi Pharm J
. 2023 May;
31(7):1210-1218.
PMID: 37256102
Background: Oseltamivir has been used as adjunctive therapy in the management of patients with COVID-19. However, the evidence about using oseltamivir in critically ill patients with severe COVID-19 remains scarce....
9.
Aloraifi R, Alharthi A, Almefleh A, Alamri A, Alobud A, Bawazeer R, et al.
Cureus
. 2023 Jan;
15(1):e33767.
PMID: 36655153
Background Antibiotics significantly increased life expectancy and decreased mortality rates due to infections. However, this trend is starting to fade with the rise of multidrug-resistant organisms (MDR); these strains are...
10.
Al Sulaiman K, Aljuhani O, Korayem G, Altebainawi A, Al Harbi S, Al Shaya A, et al.
Front Public Health
. 2022 Aug;
10:877944.
PMID: 36033795
Background: The cardiovascular complications of Coronavirus Disease 2019 (COVID-19) may be attributed to the hyperinflammatory state leading to increased mortality in patients with COVID-19. HMG-CoA Reductase Inhibitors (statins) are known...